Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
NHS gene testing does not detect half of people at cancer risk
NHS guidelines for gene testing miss half of people carrying inherited genetic changes linked to cancer, a new study reports.
NICE misses golden opportunity to enhance access to innovative cancer drugs
Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity to ensure its evaluation methods support approval of the most innovative, potentially game-changing drugs.
Focused sound waves and immunotherapy combination shows promise in pancreatic cancers
Combining targeted, focused ultrasound and immunotherapy drugs could work as a new treatment for pancreatic cancers, a new study has shown.
ICR ranks top in UK for student satisfaction
Students on our MSc taught course and postgraduate research degree programmes have again ranked The Institute of Cancer Research, London, top nationally for student satisfaction in their respective surveys.
World Cancer Day: how our new virtual centre will enhance global cancer research and tackle inequality
The Centre for Global Oncology will help to to connect and develop cancer scientists around the world.
Study uncovers how cancers resist targeted treatment
Scientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide.
ICR responds to NICE decision not to recommend olaparib for advanced prostate cancer
The Institute of Cancer Research, London, has expressed disappointment that NICE has decided not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer.
First clinical trial of innovative drug targeting HSF1 pathway begins
The first cancer patients are to receive doses of an innovative new drug that targets a master regulatory pathway in cells, as part of a new clinical trial.
Abiraterone could halve risk of prostate cancer death for some patients
Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading*, could halve the risk of death from the disease.
Carols from Chelsea celebrates festive season and our world-leading research
We welcomed back guests to our flagship annual social and fundraising event, Carols from Chelsea, at the Royal Hospital Chelsea on the 7 December.
Meet our new team members
New faces have joined the Business and Innovation Office here at The Institute of Cancer Research, London since our last newsletter. They’re helping us further expand our work with industry and academic partners.
ICR in new collaboration to develop ‘next generation’ immunotherapy candidate
Scientists at The Institute of Cancer Research, London, are working with the Cambridge-based immuno-oncology company Crescendo Biologics on its development of a potential ‘next generation’ immunotherapy.